PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study
نویسندگان
چکیده
منابع مشابه
In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PET
Objective(s): The ability to measure cellular proliferation non-invasively in renal cell carcinoma may allow prediction of tumour aggressiveness and response to therapy. The aim of this study was to evaluate the uptake of 18Ffluorothymidine (FLT) PET in renal cell carcinoma (RCC), and to compare this to 18F-fluorodeoxyglucose (FDG), and to an immunohistochemical measure of cellular proliferatio...
متن کاملin vivo imaging of cellular proliferation in renal cell carcinoma using 18f-fluorothymidine pet
objective(s): the ability to measure cellular proliferation non-invasively in renal cell carcinoma may allow prediction of tumour aggressiveness and response to therapy. the aim of this study was to evaluate the uptake of 18ffluorothymidine (flt) pet in renal cell carcinoma (rcc), and to compare this to 18f-fluorodeoxyglucose (fdg), and to an immunohistochemical measure of cellular proliferatio...
متن کاملMulticenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma.
BACKGROUND Retrospective and molecular biologic data suggest that sunitinib may be effective in patients with non-clear cell renal cell carcinoma (nccRCC). PATIENTS AND METHODS Eligibility criteria included advanced nccRCC except for collecting duct carcinoma and sarcomatoid carcinoma without identifiable renal cell carcinoma subtypes. Patients were treated with 50 mg/day oral sunitinib for 4...
متن کاملCardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study.
Our aim was to determine the feasibility of 18F-florbetaben PET in diagnosing cardiac amyloidosis. METHODS 18F-florbetaben PET was performed on 14 patients: 5 amyloid light chain, 5 amyloid transthyretin, and 4 control with hypertensive heart disease. Qualitative and quantitative assessments of 18F-florbetaben activity were performed using the SUVmean of the left ventricular myocardium and bl...
متن کاملPhase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
BACKGROUND The potential of S-1 for the treatment of metastatic renal cell carcinoma (mRCC) has been shown in two phase II studies. We aimed to assess the safety, tolerance, pharmacokinetics and clinical activity of S-1 combined with sorafenib in patients with mRCC. PATIENTS AND METHODS In this multicenter, single-arm, open-label, phase I/II study of S-1 plus sorafenib, we recruited patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Abdominal Radiology
سال: 2015
ISSN: 2366-004X,2366-0058
DOI: 10.1007/s00261-015-0599-1